Danaher came into this Q3 2026 report with the stock already grinding higher over the past three months. It then jumped another 4.3% to about $233.86 after the release. The move looks like a relief rally, yet the core story sits in the income statement. Management delivered roughly $6.6b of revenue and pushed adjusted operating margin to about 29%, while earnings per share over the trailing year reached just above $6. That combination of higher profitability and solid earnings power is what traders are paying up for today.
Love Danaher's higher margin profile but want more ideas with strong profitability baked in? Scan the broader field with our list of solid balance sheet and fundamentals stocks (25 results)
Q3 2026 Earnings Summary
-
Total Revenue (Q3 2026 vs. Q3 2025):US$6,554m vs. US$6,053m (up 8.3%)
-
Net Income (Excl. Extra Items, Q3 2026 vs. Q3 2025):US$1,207m vs. US$908m (up 33.0%)
-
Basic EPS (Q3 2026 vs. Q3 2025):US$1.71 vs. US$1.28 (up 34.3%)
-
Adjusted Operating Margin (Q3 2026 vs. Q3 2025):approximately 29.0% vs. approximately 27.9% (expansion of approximately 110 bps)
Prefer clean visuals instead of slogging through another dense block of financials and footnotes? See Danaher's full picture in an easy-to-scan format that pulls together its valuation in our company report for Danaher.
Danaher's Bull Story: Recurring Flywheel Shows Progress
The upbeat narrative around Danaher hinges on building a higher quality mix of consumables, diagnostics and cash generation that funds portfolio moves and buybacks.
"Analysts expect Danaher to continue compounding its mix of recurring consumables and diagnostics revenue, while converting earnings into strong free cash flow that supports buybacks and portfolio reshaping."
Q3 points in that direction. Diagnostics core revenue excluding respiratory grew 7%, with non respiratory Cepheid assays in the low double digits. Free cash flow reached US$1.6b in the quarter and US$4b year to date with 128% conversion, while roughly US$900m of repurchases in the first half support the capital return leg of this thesis.
Danaher Bear Case: Concentration And China Fears Tested
The cautious angle argues that heavy dependence on recurring tools and diagnostics, plus policy risk in China, could blunt the story.
"Volume based procurement and reimbursement changes in China that have already pressured Diagnostics revenue could extend beyond current expectations. Any further pricing pressure in that market would directly affect segment revenue and could compress net margins if not offset by cost efficiencies."
Current numbers show some cushion. Diagnostics ex respiratory grew mid single digits, with segment margins contributing to the roughly 110 bps adjusted operating margin expansion to about 29%. Management still calls out China pricing as a watchpoint, yet Q3 profitability suggests any ongoing pressure is being offset for now through mix, cost control and non China growth.
Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there .
Hunt For Mispriced Earnings Power
Danaher recently showed how sentiment can change when quarterly results align with the income statement. The real opportunity is finding stocks that might be undervalued before that kind of repricing occurs.
-
Company 1 - 41% below our estimate - leans into expanded manufacturing capacity and supply chains for higher margin protective films and installation channels.
-
Company 2 - 40% below our estimate - expands a premium teahouse network while a rapidly growing membership base deepens loyalty and lifts order frequency.
-
Company 3 - 39% below our estimate - scales a device recommerce platform as policy-supported trade in programs and changing recycling habits increase used electronics supply.
That is three of the list. See the full list of 33 companies trading below our fair value estimates →
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include DHR .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
